Sana faces a class action for allegedly misleading investors about finances and drug programs, says Robbins LLP.

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to ...

The suit alleges the Seattle-based biotech misled investors regarding its funds and the effectiveness of some of its ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 11.16%, which has investors questioning if this is right time to buy.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA ...

Teacher Retirement System of Texas boosted its stake in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 20.3% in the fourth quarter, HoldingsChannel reports. The firm owned 36,797 shares of ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Sana is enrolling patients in both the GLEAM and VIVID trials and expects to share data from each study in 2025. in vivo CAR T cells – SG299, which uses our fusogen platform, allows for cell ...

The suit alleges the Seattle-based biotech misled investors regarding its funds and the effectiveness of some of its treatment candidates. Seattle-based Sana Biotechnology Inc. (Nasdaq ...

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws ...

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells ...